News Headlines

31. EVA Pharma And Zhejiang Jinhua CONBA Bio-Pharm Sign Strategic Supply Agreement 6/30/2025

    EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and Zhejiang Jinhua CONBA, one of China’s most prominent pharmaceutical groups, have entered into a strategic supply agreement, marking a significant step forward in global healthcare collaboration.

32. Simtra BioPharma Solutions Expands Halle/Westfalen, Germany Facility With The Addition Of A New Production Building 6/30/2025

    Simtra BioPharma Solutions announced today that it completed the construction of its new production manufacturing building at its campus in Halle, Germany. As a leader in the CDMO industry specializing in sterile injectables, Simtra is strengthening its presence across North America and Europe to meet the growing global demand for critical injectable therapeutics.

33. Piramal Pharma Solutions Breaks Ground On $90M Expansion Plan 6/30/2025

    Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated offering.

34. Torrent Pharma To Acquire Controlling Stake In J. B. Chemicals & Pharmaceuticals From KKR 6/29/2025

    Torrent Pharmaceuticals Limited (“Torrent”) and global investment firm KKR today announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals (“JB Pharma”) from KKR at an Equity Valuation of INR 25,689 crores (on fully diluted basis), followed by a merger of the two entities.

35. Mabwell Announces Novel Drug Technology License Agreement With Qilu Pharmaceutical For Albipagrastim Alfa For Injection 6/27/2025

    Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511).

36. ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey To Advance Cell And Gene Therapy 6/27/2025

    ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey.

37. eXoZymes Selected As Core Industry Partner In $9M NSF-Funded Initiative To Advance Modular Cell-Free Biomanufacturing 6/26/2025

    Today, eXoZymes Inc. ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2M USD National Science Foundation (NSF) funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications.

38. Porton Advanced And EVA Pharma Sign MOU To Expand CAR T-Cell Therapy Access In The Middle East And Africa 6/26/2025

    Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, have announced the signing of Memorandum of Understanding (MOU) today, which will see the two organizations collaborating on establishing and strengthening CAR T-cell therapy development and manufacturing capabilities at EVA Pharma's facilities.

39. GenSight Biologics Announces Significant Milestone In New Manufacturing Partnership With Catalent 6/26/2025

    GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ, the Company’s gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc.

40. Vector BioMed And Muni Seva Ashram Partner To Bring CAR-T Cell Therapy To Rural India 6/25/2025

    This collaboration positions Vector BioMed as the preferred and exclusive CVDMO partner for KCHRC's cell therapy program, helping expand affordable CAR-T cancer treatment to underserved populations.